ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0073

Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019

Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

1:00PM-3:00PM: Abstract Number: 0402

Opioid Use and Healthcare Utilization in Adults with PsA and AS

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0006

Oral Administration of a Novel Pyrrolopyrimidine Derivative That Inhibits BAFF Signaling Suppresses B Cell Differentiation and Production of Autoantibody in Autoimmune Model Mice

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 0325

Ordering Practices and Diagnostic Utility of Cardiac MRI in SLE Patients at a Single Academic Institution

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0437

Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0086

Patient and Provider Perspectives on Barriers to Communication and Care of Latinx Patients with Lupus and Rheumatoid Arthritis

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: PP02

Patient Mobilization for Vaccine Access and Improved Care During the COVID Pandemic

Patient Perspectives Poster

1:00PM-3:00PM: Abstract Number: 0181

Patient Perspective of Unique Support and Education Needs of Latinx/Latino(a)/Hispanic Rheumatoid Arthritis Patients: Implications for a Culturally Tailored and Disease Specific Intervention

Patient Education/Community Programs Poster

1:00PM-3:00PM: Abstract Number: 0198

Patient Perspectives on Janus Kinase Inhibitor Use in the Treatment of Inflammatory Arthritis

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0187

Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0441

Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort

Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

1:00PM-3:00PM: Abstract Number: 0191

Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties

Patient Outcomes, Preferences, and Attitudes Poster I

1:00PM-3:00PM: Abstract Number: 0036

Patient-specific and Disease-related Determinants for Cardiovascular Disease (CVD) Risk Stratification in the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Clinical Trial Cohort

Pediatric Rheumatology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: PP22

Patients Raising Awareness for Patients – A Collaborative Partnership Between Take a Pain Check Foundation and Canadian Arthritis Patient Alliance

Patient Perspectives Poster

1:00PM-3:00PM: Abstract Number: 0256

Patients with ACPA-positive and ACPA-negative Rheumatoid Arthritis Show Different Circulating Auto-antibody Repertoires

RA – Diagnosis, Manifestations, and Outcomes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].